Should You Buy Agenus Inc (AGEN) Stock on Wednesday?

Agenus Inc (AGEN) stock has gained 1.28% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Agenus Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AGEN!

See Full AGEN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With AGEN Stock Today?

Agenus Inc (AGEN) stock is lower by -0.83% while the S&P 500 has gained 0.32% as of 9:49 AM on Wednesday, Nov 1. AGEN is down -$0.01 from the previous closing price of $0.80 on volume of 645,941 shares. Over the past year the S&P 500 has gained 8.66% while AGEN is down -67.89%. AGEN lost -$0.83 per share in the over the last 12 months.

More About Agenus Inc

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Click Here to get the full Stock Report for Agenus Inc stock.